[1] Rawlins, M D. Spontaneous reporting of adverse drug reactions. I: the data[J]. Br J Clin Pharmacol,1988,26(1): 1-5.
[2] Rawlins, M D. Spontaneous reporting of adverse drug reactions. II: Uses[J]. Br J Clin Pharmacol, 1988,26(1): 7-11.
[3] Finney, D J. The design and logic of a monitor of drug use[J].J Chronic Dis, 1965,18: 77-98.
[4] Napke, E. Drug adverse reaction alerting program[J].Canad Pharm J,1968,20:251-254.
[5] Finney, D J Systematic signalling of adverse reactions to drugs[J]. Meth Inf Med, 1974,13: 1-10.
[6] Napke, E. The Canadian drug adverse reaction reporting program[J]. Drug Inf J, 1975,9(2-3): 224-232.
[7] Moore,N F Thiessard,B Begaud. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions[J].Pharmacoepid-emiol Drug Saf 2005,14(4): 285-286.
[8] Hochberg, A M M Hauben, R K Pearson, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database[J].Drug Saf,,2009,32(6):509-525.
[9] van Puijenbroek,E P A Bate, H G Leufkens, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf,2002,11(1): 3-10.
[10] Kubota, K D Koide,T Hirai. Comparison of data mining metho-dologies using Japanese spontaneous reports[J]. Pharmacoepidemiol Drug Saf, 2004,13(6):387-394.
[11] Hammond, I W D S Rich,T G Gibbs. Effect of consumer reporting on signal detection: using disproportionality analysis[J].Expert Opin Drug Saf,2007,6(6): 705-712.
[12] Hauben, M D. Madigan, C M. Gerrits, et al. The role of data mining in pharmacovigilance[J]. Expert Opin Drug Saf, 2005,4(5):929-948.
[13] Almenoff, J J M. Tonning, A L Gould, et al. Perspectives on the use of data mining in pharmacovigilance[J]. Drug Saf, 2005, 28(11): 981-1007.
[14] Stricker, B H J G. Tijssen. Serum sickness-like reactions to cefaclor[J]. J Clin Epidemiol,1992,45(10): 1177-1184.
（因版面有限,部分参考文献省略,如有需要,请联系编辑部） |
